Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 6/20 | 1.00 |
| ▸ | ACE | P12821 | 3/20 | 1.00 |
| ▸ | MME | P08473 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
| ▸ | ERAP2 | Q6P179 | 4/20 | 0.53 |
| ▸ | ERAP1 | Q9NZ08 | 3/20 | 0.51 |
| ▸ | IL1RN | P18510 | 2/20 | 0.51 |
| ▸ | ANPEP | P15144 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoramidon SCHEMBL17813729 | 1.00 | ECE1 (1.00) | ECE1ACEMMELMNAERAP2 | |
| Phosphoramidon SCHEMBL9100804 | 1.00 | ECE1 (1.00) | ECE1ACEMMELMNAERAP2 | |
| Phosphoramidon SCHEMBL4436662 | 1.00 | ECE1 (1.00) | ECE1ACEMMELMNAERAP2 | |
| Phosphoramidon SCHEMBL40933 | 1.00 | ECE1 (1.00) | ECE1ACEMMELMNAERAP2 | |
| Phosphoramidon SCHEMBL14503212 | 1.00 | ECE1 (1.00) | ECE1ACEMMELMNAERAP2 | |
| Phosphoramidon SCHEMBL8189183 | 1.00 | ECE1 (1.00) | ECE1ACEMMELMNAERAP2 | |
| Phosphoramidon SCHEMBL7155564 | 1.00 | ECE1 (1.00) | ECE1ACEMMELMNAERAP2 | |
| Phosphoramidon SCHEMBL8029985 | 1.00 | ECE1 (1.00) | ECE1ACEMMELMNAERAP2 | |
| Phosphoramidon SCHEMBL7300320 | 1.00 | ECE1 (1.00) | ECE1ACEMMELMNAERAP2 | |
| SCHEMBL20179087 | 0.87 | ECE1 (0.78) | ECE1ACEMMELMNAERAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4829785-B2 | — | — | 2011-12-07 | — | — | JP | claimed |
| EP-1653997-A1 | METHODS AND COMPOSITIONS FOR CONTROLLING ECTOPARASITES | Hatchtech Pty Ltd (AU) | 2006-05-10 | — | — | EP | claimed |
| WO-2005007188-A1 | METHODS AND COMPOSITIONS FOR CONTROLLING ECTOPARASITES | HATCHTECH PTY LTD (AU) | 2005-01-27 | — | — | WO | claimed |
| US-10828368-B2 | Therapeutic treatments using centhaquin | MIDWESTERN UNIVERSITY (US) | 2020-11-10 | — | — | US | disclosed |
| US-20180085461-A1 | Novel Therapeutic Treatments Using Centhaquin | MIDWESTERN UNIVERISTY | 2018-03-29 | — | — | US | disclosed |
| US-9839631-B2 | Methods and compositions for controlling ectoparasites | DR. REDDY'S LABORATORIES, S.A. (CH) | 2017-12-12 | — | — | US | disclosed |
| US-20160367535-A1 | Methods and Compositions for Controlling Ectoparasites | HATCHTECH PTY LIMITED (AU) | 2016-12-22 | — | — | US | disclosed |
| US-9357783-B2 | Methods and compositions for controlling ectoparasites | HATCHTECH PTY LTD. (AU) | 2016-06-07 | — | — | US | disclosed |
| EP-2424530-B1 | METHOD AND COMPOSITION FOR TREATING DIABETIC KETOACIDOSIS | UNIV MIDWESTERN (US) | 2015-12-16 | — | — | EP | disclosed |
| US-20150182583-A1 | METHODS FOR TREATMENT AND PREVENTION OF TAUOPATHIES BY INHIBITING ENDOTHELIN RECEPTORS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-07-02 | — | — | US | disclosed |
| US-20150126401-A1 | CALPROTECTIN AND HEMOGLOBIN/HAPTOGLOBIN COMPLEX FROM STOOL SAMPLE TO ASSESS COLORECTAL CANCER | ROCHE DIAGNOSTICS GMBH (DE) | 2015-05-07 | — | — | US | disclosed |
| EP-0831793-A1 | PROTEIN PARTICLES FOR THERAPEUTIC AND DIAGNOSTIC USE | HEMOSPHERE, INC. (US) | 1998-04-01 | — | — | EP | disclosed |
| US-5725804-A | ALBUMIN PARTICLES STABLE TO RESOLUBILIZATION, POLYOXYETHYLENE GLYCOL, ALCOHOL | HEMOSPHERE, INC. (US) | 1998-03-10 | — | — | US | disclosed |
| WO-1998008932-A1 | INSECTICIDAL PROTEIN TOXINS FROM $I(PHOTORHABDUS) | DOW AGROSCIENCES LLC (US) | 1998-03-05 | — | — | WO | disclosed |
| EP-0797659-A1 | INSECTICIDAL PROTEIN TOXINS FROM PHOTORHABDUS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1997-10-01 | — | — | EP | disclosed |
| WO-1997017432-A1 | INSECTICIDAL PROTEIN TOXINS FROM PHOTORHABDUS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1997-05-15 | — | — | WO | disclosed |
| US-5616311-A | AQUEOUS ALBUMIN SUSPENSION STABILIZED BY HEMOGLOBIN PARTICLES | HEMOSPHERE, INC. (US) | 1997-04-01 | — | — | US | disclosed |
| EP-0759074-A1 | STABILIZING SOLUTIONS FOR PROTEINS AND PEPTIDES | DADE INTERNATIONAL INC. (US) | 1997-02-26 | — | — | EP | disclosed |
| WO-1996039128-A1 | PROTEIN PARTICLES FOR THERAPEUTIC AND DIAGNOSTIC USE | HEMOSPHERE, INC. (US) | 1996-12-12 | — | — | WO | disclosed |
| WO-1996027661-A1 | STABILIZING SOLUTIONS FOR PROTEINS AND PEPTIDES | DADE INTERNATIONAL INC. (US) | 1996-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10828368-B2 | Therapeutic treatments using centhaquin | ADRA2A, ADRB3, HSPH1 | ECE1 404/4885ACE 172/4885MME 68/4885 |
| US-20160367535-A1 | Methods and Compositions for Controlling Ectoparasites | CAT, CMA1, CTRL | ECE1 259/4885ACE 265/4885MME 12/4885 |
| US-20150182583-A1 | METHODS FOR TREATMENT AND PREVENTION OF TAUOPATHIES BY INHIBITING ENDOTHELIN RECEPTORS | EDNRB, EDNRA, ECE1 | ECE1 3/4885ACE 1047/4885MME 38/4885 |
| US-20180085461-A1 | Novel Therapeutic Treatments Using Centhaquin | ADRB3, ADRA2A, ADRB2 | ECE1 267/4885ACE 307/4885MME 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.